Intraaortic balloon pumping (IABP) is a useful therapy for refractory heart failure. However, the safe duration of this therapy and possible complications due to long-term IABP support remain unclear. In this study, we reviewed retrospectively patients requiring the long-term use of IABP, defined here as 10 days or more, to estimate the background and prognosis of patients undergoing long-term use of IABP. The characteristics and perioperative status were compared between survivors and nonsurvivors.
INTRAAORTIC balloon pumping (IABP) therapy was first used clinically in
1968 by Kantrowitz and colleagues 1) for supporting patients with cardiogenic shock after acute myocardial infarction. The usefulness of IABP has been recently recognized for the treatment of refractory heart failure, and the indication for IABP has been increasing over the last three decades.
2) The most common indication of balloon pumping support is heart failure not only due to myocardial infarction, but also during and after surgery with cardiopulmonary bypass, and in patients with severe heart disease who are undergoing noncardiac procedures. The IABP use in these cases is usually short-term, and the management is directed toward rapid removal as indications for placement are resolved. On the other hand, some patients require IABP over the long-term to maintain their hemodynamics. However, few reports about long-term IABP support have been published, and the safe duration of IABP use, possible complications, and prognosis of patients with long-term IABP support are still unclear. In this study, we investigated the background and prognosis of patients undergoing long-term IABP use of 10 days or more.
METHODS
We retrospectively analyzed patients who had undergone long-term IABP treatment (more than 10 days) in the Intensive Care Unit (ICU) of Gunma University Hospital between January 1, 1992 and December 31, 2003. All patients required long-term IABP support for severe heart failure and/or maintenance of coronary flow. Severe heart failure was defined by the presence of the following criteria: 1) peak systolic pressure was less than 80 mmHg for more than a few hours after correction of hypovolemia, hypoxemia, and acidosis with administration of a sufficient dose of catecholamine, 2) urine volume was less than 0.5 mL/ kg/hr for more than a few hours, and 3) the presence of peripheral signs of hypoperfusion. The decision to initiate and prolong IABP therapy was up to the attending physician. The balloon was inserted from the right or left femoral artery using the Seldinger technique. Recently, we have been using a T.M.P. IABP balloon catheter (8Fr or 7Fr, Tokai Medical Products Co., Aichi, Japan) and a XEMEX IABP Console 908 (Xeon Medical Co., Tokyo) for IABP therapy.
Patients were divided into two groups, survivors and nonsurvivors, to identify differences between the two groups and predictors for survival with the longterm use of IABP. We analyzed age, gender, duration of IABP use, ICU stay and respiratory support, left ventricular ejection fraction (LVEF) measured with ultracardiography (UCG), incidence of multiple organ failure (MOF), use of other circulatory assists such as a percutaneous cardiopulmonary support system (PCPS) and ventricular assist device (VAD), presence of preoperative IABP use, times of IABP installation, preoperative use of catecholamine, and continuous hemodiafiltration (CHDF) or hemodialysis (HD) use. MOF was defined by the presence of respiratory failure {respiratory index (RI) ≥ 1.5, requiring mechanical ventilation}, renal failure (urine volume ≤ 0.5 mL/kg/hr, serum creatinine level ≥ 2.0 mg/dL, and/or need for CHDF or HD), and liver failure (serum total bilirubin level ≥ 5.0 mg/dL) in addition to heart failure.
The 3 criteria for IABP weaning, ie, reduction of the IABP support rate and then removal of IABP, were as follows; the systolic pressure of a patient undergoing long-term IABP was kept at 90 mmHg or more, the cardiac index was maintained at more than 2.2 L/min/m 2 , and the pulmonary capillary wedge pressure was kept at less than 18 mmHg. Statistical analysis: Data are shown as the mean ± standard deviation, and the unpaired t-test or χ 2 analysis was used to compare variables between survivors and nonsurvivors. A multivariate logistic regression model was used to detect independent predictors of survival. StatView software version 5.0 (Abacus, Berkeley, CA) was used for statistical analysis. Statistical significance was assumed at a P value of less than 0.05.
RESULTS
From January 1992 to December 2003, a total of 18 patients were treated with long-term IABP use (mean duration, 17 ± 7 days, range, 10 to 39 days). There were 12 men (67%) and 6 women (33%). The mean age was 66 ± 15 years and the range was 14 to 79. Beta-blockers were not administered to patients during the treatment with IABP. The mean duration of ICU stay and respiratory support was 36 ± 29 days and 30 ± 23 days, respectively.
Severe heart failure in 18 patients occurred due to the reasons shown in Table I ; 13 after cardiac surgery and the other 5 without surgery. The surgical procedures performed are shown in Table II . Coronary artery bypass grafting (CABG) was the main operation, including 4 emergency cases (two patch closures for ventricular septal perforation, one CABG, and one CABG + mitral valvoplasty). Seven patients survived and 11 died of heart failure and/or associated other organ failure (MOF occurred in 9 patients).
Tables III and IV show comparisons of the characteristics between survivors and nonsurvivors. There were no significant differences in age or gender between the 2 groups. The duration of IABP use and duration of respiratory support were shorter in survivors than in nonsurvivors (NS). LVEF was low in both groups at the time of IABP induction, however, LVEF improved and was significantly (P = 0.002) better in survivors (47 ± 18%) than in nonsurvivors (21 ± 7%). No improvement of LVEF was found in nonsurvivors. The incidence of MOF was significantly (P = 0.005) higher in nonsurvivors (82%) than in survivors (14%). The percentage of patients who underwent cardiac surgery was also significantly (P = 0.027) higher in nonsurvivors (91%) than in survivors (43%). On the other hand, only one patient died due to respiratory failure and there was no case with MOF among the 5 patients without cardiac surgery. The use of other circulatory assist devices, preoperative IABP support, preoperative use of catecholamine, and CHDF or HD use were also slightly higher in nonsurvivors than in survivors. However, there were no significant differences between the 2 groups. Multivariate logistic regression analysis indicated that the occurrence of MOF and postcardiac surgery patient were the parameters that were statistically significant predictors for the survival of patients undergoing long-term use of IABP (Table V) .
A femoral arterial-venous fistula was the only IABP-related complication in patients with the long-term use of IABP, and no other complications contributory to death occurred.
DISCUSSION
IABP therapy has been established as a valuable mechanical support for temporary ventricular assistance in the treatment of cardiac failure. 3, 4) The main effects of IABP support are an improvement of diastolic coronary perfusion, enhancement of subendocardial perfusion, and reduction of ventricular afterload.
5) The clinical efficacy of IABP for short-term support has been frequently reported, however, only a few reports have documented the long-term use of IABP.
6,7) Freed and colleagues described 24 patients with prolonged IABP support of 20 days or more 6) and found that complications were more frequent in prolonged-support patients than in those assisted for less than 20 days, and that the − survival rate of prolonged-support patients was 63%. Manord and co-workers studied patients who underwent prolonged (greater than 72 hours) IABP use and reported that prolonged IABP therapy was feasible and associated with an acceptable rate of complications. They indicated that surgical removal of an IABP catheter was superior to percutaneous removal. In 18 patients who required long-term IABP support of 10 days or more, an IABP-related complication occurred in only one patient with femoral arterial-venous fistula. We did not use any anticoagulation protocol. The low frequency of complications might be due to improved insertion techniques and improved catheter quality. In addition, 14 patients (78%) were intravenously administered nafamostat mesilate because of the induction of CHDF or HD. Noel and colleagues reported their experience with percutaneous insertion of IABP through the brachial artery using a thin and flexible catheter. 8) Thus, the prolonged use of IABP now appears to be acceptable and safe. LVEF in survivors was improved within 10 days after IABP induction, however, an improvement was not seen in nonsurvivors. Four (80%) of 5 patients without cardiac surgery survived. One died due to respiratory failure and none of the 5 had MOF. As a result, the 4 patients without cardiac surgery (57%) were included in the 7 survivors, while one patient without cardiac surgery (9%) was included in the 11 nonsurvivors. Multivariate logistic regression analysis demonstrated that MOF and cardiac surgery were independent factors for death in patients with long-term IABP support. In the present study, MOF occurred due to hypoperfusion caused by prolonged cardiac failure. IABP is an easily inducible and useful technique for the treatment of cardiac failure. However, IABP function is limited for supporting the hemodynamics of a patient because cardiac output increases only up to 15% with IABP support. Other circulatory assist devices such as PCPS or VAD which increase tissue perfusion should be induced before MOF develops. Patients at the time when PCPS was not widely available and LVAD induction was more complicated and invasive were included in the present study, indicating that the induction of additive circulatory assist was delayed. The reason why there was no significant difference between the survivors and nonsurvivors in the use of PCPS is probably due to the small number of patients in this series. A larger patient population is needed to allow the detection of predictors of mortality.
In conclusion, the prolonged use of IABP is acceptable, however, other circulatory assists should be taken into consideration if IABP function alone is insufficient at improving the hemodynamics of the patient because prolonged cardiac failure is the cause of hypoperfusion of other organs and induces MOF, resulting in high mortality rates.
